JAZZ Stock Recent News

Jazz Pharmaceuticals is rated as a "Buy" due to its current financial health, multiple near-term catalysts, and projected growth for 2024 and 2025. The company's successful commercial products include Xywav, Epidiolex, and Rylaze, which have shown increasing adoption and sales revenues. JAZZ is targeting low-hanging fruit in oncology with its drug Zanidatamab, which has the potential to become a blockbuster drug with up to $2 billion/year in net sales.

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.

Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.02 per share, missing the Zacks Consensus Estimate of $5.26 per share. This compares to loss of $0.07 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

While many top cannabis stocks have existed for years, the U.S. market has warmed up to the cannabinoid sector only recently. About 40 states allow the use of cannabis, although not all permit its recreational administration.

DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

Biotech investing is not for impatient investors. So why is it attractive to some investors?